Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of rapcabtagene autoleucel versus investigator's choice in severe refractory idiopathic inflammatory myopathies
jRCT2013240052Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jan 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in Autoimmune Myopathies (2 arms), sponsored by Novartis. Primary endpoint: Proportion of participants achieving at least moderate improvement in Total Improvement Score. Started Jan 2025; status: suspended.
02
Drugs
rapcabtagene autoleucel
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on jRCT2013240052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013240052.